

## **COVID-19 is associated with multiple sclerosis exacerbations that are prevented by disease modifying therapies**

Afagh Garjani <sup>1,2</sup>, Rodden M Middleton <sup>3</sup>, Rachael Hunter <sup>4</sup>, Katherine A Tuite-Dalton <sup>3</sup>, Alasdair Coles <sup>5</sup>, Ruth Dobson <sup>6</sup>, Martin Duddy <sup>7</sup>, Stella Hughes <sup>8</sup>, Owen R Pearson <sup>9</sup>, David Rog <sup>10</sup>, Emma C Tallantyre <sup>11</sup>, Roshan das Nair <sup>12,13</sup>, Richard Nicholas <sup>14</sup>, Nikos Evangelou <sup>1,2</sup>

<sup>1</sup> Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham

<sup>2</sup> Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK

<sup>3</sup> Population Data Science, Swansea University Medical School, Swansea, UK

<sup>4</sup> College of Health and Human Science, Swansea University, Swansea, UK

<sup>5</sup> Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK

<sup>6</sup> Preventive Neurology Unit, Queen Mary University London, London, UK

<sup>7</sup> Neurosciences, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK

<sup>8</sup> Department of Neurology, Belfast Health and Social Care Trust, Belfast, UK

<sup>9</sup> Neurology Department, Swansea Bay University Health Board, Swansea, UK

<sup>10</sup> Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK

<sup>11</sup> Division of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK

<sup>12</sup> Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
of Nottingham

<sup>13</sup> Institute of Mental Health, Nottinghamshire Healthcare NHS Foundation Trust,  
Nottingham, UK

<sup>14</sup> Department of Cellular and Molecular Neuroscience, Imperial College London, London,  
UK

**Corresponding Author:**

Nikos Evangelou

Address: C Floor, South Block, Department of Academic Clinical Neurology, Queen's  
Medical Centre, Nottingham NG7 2UH, United Kingdom

Email: [nikos.evangelou@nottingham.ac.uk](mailto:nikos.evangelou@nottingham.ac.uk)

Telephone: +44 (0) 115 970 9735

Fax: +44 (0) 115 970 9493

## ABSTRACT

**Background:** Infections can trigger exacerbations of multiple sclerosis (MS). The effects of the coronavirus disease 2019 (COVID-19) on MS are not known. The aim of this study was to understand the impact of COVID-19 on new and pre-existing symptoms of MS.

**Methods:** The COVID-19 and MS study is an ongoing community-based, prospective cohort study conducted as part of the United Kingdom MS Register. People with MS and COVID-19 were invited by email to complete a questionnaire about their MS symptoms during the infection. An MS exacerbation was defined as developing new MS symptoms and/or worsening of pre-existing MS symptoms.

**Results:** Fifty-seven percent (230/404) of participants had an MS exacerbation during their infection; 82 developed new MS symptoms, 207 experienced worsened pre-existing MS symptoms, and 59 reported both. Disease modifying therapies (DMTs) reduced the likelihood of developing new MS symptoms during the infection (OR 0.556, 95%CI 0.316-0.978). Participants with a higher pre-COVID-19 webEDSS (web-based Expanded Disability Status Scale) score (OR 1.251, 95%CI 1.060-1.478) and longer MS duration (OR 1.042, 95%CI 1.009-1.076) were more likely to experience worsening of their pre-existing MS symptoms during the infection.

**Conclusion:** COVID-19 infection was associated with exacerbation of MS. DMTs reduced the chance of developing new MS symptoms during the infection.

**Key words:** Multiple sclerosis, COVID-19, infection, exacerbation, disease modifying therapies

## **INTRODUCTION**

The role of systemic infections in provoking exacerbations of multiple sclerosis (MS) is well described.<sup>1</sup> The coronavirus disease 2019 (COVID-19) is a viral infection, the effects of which on MS exacerbations have not been established. Understanding the impact of COVID-19 on MS symptoms will allow for thorough counselling of people with MS regarding the risk of infection during periods of community transmission.

Potential safety concerns about using immunosuppressive MS disease modifying therapies (DMTs) during the COVID-19 pandemic,<sup>2</sup> along with disruptions to MS services,<sup>3</sup> have resulted in changes to the treatment plans of many people with MS. However, a decrease in the use of DMTs during the pandemic could lead to excessive MS relapses. Further understanding of the relationship between COVID-19, MS relapses and DMTs will inform decision-making about altering or delaying treatment with DMTs.

In this paper, we study the impact of COVID-19 on pre-existing and new symptoms of MS in a large cohort of people with MS and COVID-19. We also assess potential factors associated with COVID-19 related MS exacerbations.

## **MATERIALS AND METHODS**

The COVID-19 and MS study is an ongoing national community-based, prospective cohort study conducted as part of the United Kingdom (UK) MS Register (UKMSR)<sup>4</sup>. People with MS report whether they have had symptoms consistent with COVID-19, whether the diagnosis was confirmed by a healthcare provider based on their clinical or laboratory findings, and whether they have been admitted to a hospital because of their infection<sup>4</sup>.

People with MS and symptoms consistent with COVID-19 were invited to complete a questionnaire about their MS symptoms during or soon after the infection between 20th of July 2020 and 25th of January 2021. We asked participants about any new or worsened pre-

existing MS symptoms. Here, we report our cross-sectional findings according to the STROBE guidelines <sup>5</sup>.

We defined an MS exacerbation as developing new MS symptoms, worsening of pre-existing MS symptoms, or experiencing both during a COVID-19 infection. We asked participants about limitation in daily activities caused by the new symptoms and classified them as mild (no limitation), moderate (less than 50% limitation), or severe (more than 50% limitation).

We correlated the COVID-19 and MS symptoms data with information held by the UKMSR on participants' demographics (age, sex, and ethnicity), clinical characteristics (MS type, disease duration from diagnosis, and DMTs), most recent recorded web-based Expanded Disability Status Scale (webEDSS) scores (scored 0 – 10, with higher scores indicating more neurological impairment) from before their infection <sup>6</sup>, and most recent Hospital Anxiety and Depression Scale scores (scored 0 – 21, with scores  $\geq 11$  considered as probable cases of anxiety or depression) <sup>7</sup>.

### **Statistical Analysis**

Data were analysed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., USA; 2019).

Continuous data were compared using the independent samples t-test, if normally distributed (mean [standard deviation, SD]) or the Mann-Whitney U test, when not normally distributed (also used for comparing ordinal variables; median [interquartile range, IQR]). Categorical variables were analysed using the Chi-square test (or Fischer's exact test if expected count  $\leq 5$ ). For variables with missing data, the number of valid values is stated.

The association between different dependent (developing new MS symptoms, worsening of pre-existing MS symptoms) and independent variables (age, sex, type of MS, MS disease duration, pre-COVID-19 webEDSS score, DMT use) was assessed using univariable or

multivariable binomial logistic regression analysis. To avoid introducing bias by controlling for colliders and mediators in the regression analyses models, directed acyclic graphs (DAGs) were built to determine confounding factors for individual regression analyses<sup>8 9</sup>.

Confounding factors controlled for in each analysis have been stated. Listwise deletion was implemented for missing data. The results of the regression analyses are presented as odds ratio (OR) and 95% confidence intervals (95% CI).

### **Standard Protocol Approvals, Registrations, and Patient Consents**

Ethical approval for UKMSR studies was obtained from South West-Central Bristol Research Ethics Committee (16/SW/0194). Participants provided informed consent online. The study is registered on [clinicaltrials.gov](https://clinicaltrials.gov): NCT04354519.

### **Data Availability Policy**

Data are stored on the UKMSR Secure e-Research Platform at Swansea University Medical School. Line level data cannot be released, but qualified researchers, subject to governance, can request access to data.

## **RESULTS**

We invited 978 people with MS and COVID-19 to complete the MS symptoms questionnaire and 404 (41%) responded within a median (IQR) duration of 14 (9 – 17) weeks from reporting a diagnosis of COVID-19 (Table 1).

Table 1. Demographic and clinical characteristics of participants and non-participants

	Participants (n =404)	Non-participants (n =574)	<i>p</i> value
Age, years, mean (SD)	50 (11)	48 (11)	0.001
Female, n (%)	307 (76)	456 (79.4)	0.434

White ethnicity, n (%)	380 (94.1)	538 (93.7)	0.832
Pre-COVID-19 webEDSS score <sup>a</sup> , median (IQR)	4.5 (3 – 6.5) n =248	4 (3 – 6.5) n =288	0.776
MS type, n (%)			
RRMS	277 (68.6)	415 (72.3)	0.018
SPMS	65 (16.1)	99 (17.2)	
PPMS	39 (9.7)	26 (4.5)	
Unknown	23 (5.7)	34 (5.9)	
MS disease duration, years, median (IQR)	11 (5 – 18) n =395	10 (5 – 17) n =547	0.106
DMTs, n (%)	193 (47.8)	301 (52.4)	0.151
Beta interferons	21 (5.2)	39 (6.8)	
Glatiramer acetate	22 (5.4)	37 (6.5)	
Teriflunomide	7 (1.7)	14 (2.4)	
Dimethyl fumarate	58 (14.4)	72 (12.6)	
Fingolimod	24 (5.9)	35 (6.1)	
Siponimod	0 (0)	1 (0.2)	
Natalizumab	24 (5.9)	44 (7.7)	
Ocrelizumab	14 (3.5)	33 (5.8)	
Cladribine	7 (1.7)	9 (1.6)	
Alemtuzumab	13 (3.2)	15 (2.6)	
Others <sup>b</sup>	3 (0.7)	1 (0.2)	
Confirmed COVID-19, n (%)	108 (26.7)	168 (29.3)	

Hospitalized due to COVID-19, n (%)	8 (2)	9 (1.6)	0.620
<p>DMTs = Disease Modifying Therapies; IQR = Interquartile Range; PPMS = Primary Progressive MS; RRMS = Relapsing Remitting MS; SD = Standard Deviation; SPMS = Secondary Progressive MS; webEDSS = web-based Expanded Disability Status Scale</p> <p><sup>a</sup> The median (IQR) duration from recording the webEDSS score to reporting COVID-19 was 7 (3 – 16.75) weeks for participants and 11 (6 – 23.75) weeks for non-participants (<math>p &lt; 0.001</math>).</p> <p><sup>b</sup> Participants were taking Ponesimod (n =1) and Rituximab (n =2) and the non-participant was taking Azathioprine.</p>			

Two hundred and thirty (57%) participants had an MS exacerbation, with 82 (20%) developing new symptoms, 207 (51%) experiencing worsened pre-existing symptoms, and 59 (15%) reporting both during their COVID-19 infection.

Ninety-seven percent (n =222) of participants with an MS exacerbation (80 with new MS symptoms and 199 with worsened pre-existing MS symptoms) had fever during their infection compared to 68% (n =72) of participants without an MS exacerbation ( $p < 0.001$ ). Six (3%) participants with an MS exacerbation (2 with new MS symptoms and all 6 with worsened pre-existing MS symptoms) and 2 (1%) participants without an MS exacerbation were hospitalized due to COVID-19 ( $p = 0.296$ ).

The rate of MS exacerbations was not significantly different between participants with (n =108) and without (n =296) a confirmed diagnosis of COVID-19 (63.9% vs 54.4%,  $p = 0.088$ ).



A higher proportion of participants with anxiety and/or depression reported an MS exacerbation during their infection compared to participants without anxiety or depression (68% [78/114] vs 51% [109/212],  $p=0.003$ ), with 32% ( $n=36$ ) and 14% ( $n=30$ ) reporting new MS symptoms, respectively, and 61% ( $n=69$ ) and 48% ( $n=101$ ) reporting worsened pre-existing MS symptoms, respectively.

Thirty-nine percent (77/196) of the participants with an MS exacerbation required additional support for their daily activities during COVID-19 infection, as opposed to only 6% (7/114) of the participants without an exacerbation ( $p<0.001$ ).

### New MS Symptoms

Among the 82 participants with new MS symptoms during the infection, the most reported new symptoms were sensory, motor, or both ( $n=58$ ; 71%) (Table 2). Some COVID-19 symptoms such as fatigue, memory problems, or mobility problems can mimic MS symptoms. Most participant who reported fatigue ( $n=18$ ), memory problems ( $n=17$ ), or mobility problems ( $n=24$ ) as part of their new MS symptoms during the infection had additional non-COVID-19 related neurological symptoms including sensory, motor, visual, or balance problems (89%, 88%, and 71%, respectively).

Table 2. Reported new multiple sclerosis symptoms during COVID-19 infection

	N (%)
Symptoms <sup>a</sup>	82 (100)
Weakness	27 (6.7)
Mild	6 (22.2)
Moderate	14 (51.9)
Severe	7 (25.9)

Sensory symptoms (numbness, pins and needles, or pain)	43 (10.6)
Mild	12 (30.8)
Moderate	24 (61.5)
Severe	7 (17.9)
Balance problems	24 (5.9)
Mild	5 (20.8)
Moderate	14 (58.3)
Severe	5 (20.8)
Bladder or bowel problems	15 (3.7)
Mild	4 (28.6)
Moderate	6 (42.9)
Severe	5 (35.7)
Visual problems (blurred vision or double vision)	12 (3)
Mild	5 (41.7)
Moderate	3 (25)
Severe	4 (33.3)
Fatigue	18 (4.5)
Mild	3 (16.7)
Moderate	6 (33.3)
Severe	9 (50)
Memory problems	17 (4.2)
Mild	3 (17.6)
Moderate	9 (52.9)
Severe	5 (29.4)

Mobility problems	24 (5.9)
Mild	3 (12.5)
Moderate	13 (54.2)
Severe	8 (33.3)
Others <sup>b</sup>	10 (2.5)
<p><sup>a</sup> Symptoms causing no limitation in daily activities were considered as mild, symptoms causing less than 50% limitation in daily activities as moderate, and symptoms causing more than 50% limitation in daily activities as severe.</p> <p><sup>b</sup> Other new MS symptoms included spasms, speech or swallowing difficulties, tremor, or vertigo</p>	

Sixteen (20%) participants with new MS symptoms during their infection had mild, 40 (49%) had moderate, and 26 (32%) had severe symptoms. None were treated with steroids.

Taking DMTs reduced the likelihood of developing new MS symptoms during the infection (adjusted OR 0.556, 95% CI 0.316 – 0.978) (Table 3). We did not formally test the association between individual DMTs and developing new MS symptoms due to the small number of participants on individual DMTs; however, it seemed that a higher proportion of participants without new MS symptoms during their infection were taking fingolimod, ocrelizumab, or cladribine compared to participants who developed new symptoms (Table 4).

Table 3. Factors associated with changes in symptoms of multiple sclerosis

	OR	95% CI	N <sup>a</sup>	Adjustments
Developing new MS symptoms (n =82) compared to no new MS symptoms (n =322)				
Age (one-year increase)	0.997	0.975 – 1.019	404	None
Male (vs female)	0.550	0.289 – 1.048	403	None

PMS (vs RRMS)	1.532	0.814 – 2.883	395	Age, Sex, MS disease duration
MS disease duration (one-year increase)	1.024	0.991 – 1.059	395	Age
Pre-COVID-19 webEDSS score (one-point increase)	1.108	0.929 – 1.322	248	Age, Sex, Type of MS, Taking DMTs
Taking DMTs	<b>0.556</b>	<b>0.316 – 0.978</b>	404	Type of MS
Worsening of pre-existing MS symptoms (n =207) compared to no worsening (n =128) <sup>b</sup>				
Age (one-year increase)	1.016	0.995 – 1.037	335	None
Male (vs female)	0.640	0.381 – 1.077	335	None
PMS (vs RRMS)	1.147	0.625 – 2.106	327	Age, Sex, MS disease duration
MS disease duration (one-year increase)	<b>1.042</b>	<b>1.009 – 1.076</b>	327	Age
Pre-COVID-19 webEDSS score (one-point increase)	<b>1.251</b>	<b>1.060 – 1.478</b>	208	Age, Sex, Type of MS, Taking DMT
Taking DMTs	1.186	0.716 – 1.966	335	Type of MS
<p>CI = Confidence Interval; DMTs = Disease Modifying Therapies; MS = Multiple Sclerosis; OR = Odds Ratio; PMS = Progressive MS, which includes primary and secondary progressive MS; webEDSS = web-based Expanded Disability Status Scale</p> <p><sup>a</sup> Number of participants included in the analysis after listwise deletion of missing data.</p> <p><sup>b</sup> Sixty-nine participants did not recall whether their pre-existing MS symptoms had become worse or not during their COVID-19 infection.</p>				

Table 4. Characteristics of participants with and without new symptoms of multiple sclerosis during COVID-19 infection

	With new MS symptoms n =82	Without new MS symptoms n =322	<i>p</i> value
Age, years, mean (SD)	50 (11)	50 (11)	0.784
Female, n (%)	68 (82.9)	239 (74.2)	0.066
White ethnicity, n (%)	3 (3.7)	21 (6.5)	0.327
Pre-COVID-19 webEDSS score, median (IQR)	5 (2.875 – 6.5) n =50	4 (3 – 6.5) n =198	0.481
MS type, n (%)			
RRMS	53 (64.6)	224 (69.6)	0.589 <sup>a</sup>
SPMS	14 (17.1)	51 (15.8)	
PPMS	11 (13.4)	28 (8.7)	
Unknown	4 (4.9)	19 (5.9)	
MS disease duration, years, median (IQR)	11.5 (5 – 20.5) n =80	11 (6 – 17) n =315	0.564
DMTs <sup>b</sup> , n (%)	30 (36.6)	163 (50.6)	0.023
Beta interferons	4 (13.3)	17 (10.4)	
Glatiramer acetate	6 (20)	16 (9.8)	
Teriflunomide	2 (6.7)	5 (3.1)	
Dimethyl fumarate	8 (26.7)	50 (30.7)	
Fingolimod	2 (6.7)	22 (13.5)	
Natalizumab	5 (16.7)	19 (11.7)	

Ocrelizumab	1 (3.3)	13 (8)	
Cladribine	0 (0)	7 (4.3)	
Alemtuzumab	2 (6.7)	11 (6.7)	
Others <sup>c</sup>	0 (0)	3 (1.8)	
Required more help <sup>d</sup> , n (%)	28 (39.4)	68 (23.9)	0.009

DMTs = Disease Modifying Therapies; IQR = Interquartile Range; PPMS = Primary Progressive MS; RRMS = Relapsing Remitting MS; SPMS = Secondary Progressive MS; webEDSS = web-based Expanded Disability Status Scale

<sup>a</sup> One cell (12.5%) has expected count less than 5.

<sup>b</sup> Percentages of individual DMTs are calculated based on the total number of participants taking DMTs in each group.

<sup>c</sup> Participants were taking Ponesimod (n =1) and Rituximab (n =2).

<sup>d</sup> During their COVID-19 infection than before.

Thirty-six (44%) participants with new MS symptoms reported recovery from these symptoms; 21 (26%) recovered within three weeks. Among the 46 participants who had not reported recovery, the median (IQR) duration from reporting COVID-19 to reporting persistence of the symptoms was 14 (10 – 17) weeks.

### **Pre-existing MS Symptoms**

Among the 207 participants with worsened pre-existing MS symptoms during the infection (Table 5), 190 (92%) reported this worsening to be the same as (n=91) or worse than (n=99) their previous non-COVID-19 systemic infection.

Table 5. Characteristics of participants with and without worsened pre-existing symptoms of multiple sclerosis during COVID-19 infection

	With worsened pre-existing MS symptoms  n =207	Without worsened pre-existing MS symptoms  n =128 <sup>a</sup>	<i>p</i> value
Age, years, mean (SD)	51 (11)	49 (11)	0.140
Female, n (%)	166 (80.2)	93 (72.7)	0.176
White ethnicity, n (%)	197 (95.2)	117 (91.4)	0.167
Pre-COVID-19 webEDSS score, median (IQR)	4.5 (3 – 6.5)  n =133	4 (2.5 – 6.5)  n =75	0.035
MS type, n (%)			
RRMS	138 (66.7)	90 (70.3)	0.648
SPMS	36 (17.4)	18 (14.1)	
PPMS	21 (10.1)	10 (7.8)	
Unknown	12 (5.8)	10 (7.8)	
MS disease duration, years, median (IQR)	12 (7 – 19)  n =203	8 (4 – 15.75)  n =124	0.001
DMTs <sup>b</sup> , n (%)	101 (48.8)	61 (47.7)	0.840
Beta interferons	9 (8.9)	9 (14.8)	
Glatiramer acetate	11 (10.9)	6 (9.8)	
Teriflunomide	3 (3)	1 (1.6)	
Dimethyl fumarate	36 (35.6)	14 (23)	
Fingolimod	13 (12.9)	9 (14.8)	
Natalizumab	13 (12.9)	8 (13.1)	
Ocrelizumab	6 (5.9)	5 (8.2)	

Cladribine	3 (3)	4 (6.6)	
Alemtuzumab	5 (5)	5 (8.2)	
Others <sup>c</sup>	2 (1.2)	0 (0)	
Required more help <sup>d</sup> , n (%)	70 (39.8)	8 (6.6)	<0.001

DMTs = Disease Modifying Therapies; IQR = Interquartile Range; PPMS = Primary Progressive MS; RRMS = Relapsing Remitting MS; SPMS = Secondary Progressive MS; webEDSS = web-based Expanded Disability Status Scale

<sup>a</sup> Sixty-nine participants did not recall whether their pre-existing MS symptoms had become worse or not during their COVID-19 infection.

<sup>b</sup> Percentages of individual DMTs are calculated based on the total number of participants taking DMTs in each group.

<sup>c</sup> Participants were taking Ponesimod (n =1) and Rituximab (n =1).

<sup>d</sup> During their COVID-19 infection than before.

The pre-existing MS symptoms of participants with a higher pre-COVID-19 webEDSS score (adjusted OR 1.251, 95% CI 1.060 – 1.478) and longer MS disease duration (adjusted OR 1.042, 95% CI 1.009 – 1.076) were more likely to worsen during the infection (Table 3).

Sixty-three (30%) participants who experienced worsening of their pre-existing MS symptoms during the infection reported returning to baseline; 42 (20%) recovered within three weeks. Among the 144 participants who had not returned to baseline, the median (IQR) duration from reporting COVID-19 to responding to the questionnaire was 14 (9 – 16) weeks.

## DISCUSSION

This large community-based study found that 57% of people with MS and COVID-19 experience an MS exacerbation during their infection, including 20% who develop new MS



symptoms. Previous studies have demonstrated an increased risk of MS exacerbations associated with other infections,<sup>1</sup> but the rates (9% to 41%)<sup>10-14</sup> are lower than COVID-19 related exacerbations reported in this study. We could not objectively assess the reported new MS symptoms by neurological examination to confirm that they were relapses due to the restrictions caused by the pandemic. Previously, it has been shown that relapses reported by people with MS are often also diagnosed as relapses by clinicians<sup>15</sup>.

An association between DMT use and reduction of infection-related exacerbations of MS has not been conclusively established<sup>11 13</sup>. We found that taking a DMT reduces the probability of developing new MS symptoms during COVID-19 infection by 44%, which is consistent with the overall relapse rate reduction observed in clinical trials of current DMTs<sup>16</sup>. Our data suggest that different DMTs might have a variable effect in preventing COVID-19 related new MS symptoms. This very preliminary finding is interesting but needs to be confirmed in larger studies.

Studies have suggested that infection-related exacerbations can be more severe and prolonged compared to exacerbations not induced by an infection<sup>13 14</sup>. In our study, the MS exacerbation of many participants had not resolved three months after their COVID-19 infection. Most individuals with COVID-19 related worsening of their MS symptoms reported a deterioration that was worse than or similar to their previous non-COVID-19 infection. This finding could have been influenced by recall bias, however. In addition, most individuals reported that their new MS symptoms resulted in limitation of their daily activities.

We wondered whether people had regarded their COVID-19 symptoms, such as fatigue or cognitive problems that can mimic MS symptoms, as deterioration of their MS. Can we truly distinguish MS deterioration from some systemic symptoms of COVID-19? We cannot

answer this question with confidence without paraclinical tests, but we found that most individuals with fatigue, memory, or mobility problems also reported other neurological symptoms suggestive of MS.

Although more individuals with anxiety or depression reported an MS exacerbation during their COVID-19 infection than individuals without anxiety or depression, the rate of MS exacerbations was above 50% in both groups, suggesting that over-reporting of symptoms linked to anxiety or depression has not driven these results <sup>17</sup>.

## **CONCLUSIONS**

In this study, we demonstrate that COVID-19 is associated with MS exacerbations. This finding highlights the importance of protecting people with MS against the infection which is now feasible with the increasing number of COVID-19 vaccines. Fewer people taking DMTs experience new neurological symptoms following COVID-19, and, therefore, it is important to consider carefully before altering or delaying treatment with DMTs because of concerns about their safety during the pandemic.

## **STUDY FUNDING**

The research was supported by the UK MS Society (funding reference 131).

## **DISCLOSURES**

AG, RMM and KTD have received funding from the UK MS society. AG has received speaker honoraria from the MS Academy.

RH reports no conflicts of interest.

AC has received honoraria and travel support from Sanofi, up until September 2017.

RD has received speaker honoraria from Biogen Idec, Teva, Neurology Academy, and Sanofi Genzyme. She has received research support from Biogen, Merck, and Celgene.

MD has received personal honoraria for speaking, advisory boards, participation in research and travel expenses from Bayer, Biogen, Celgene (BMS), Merck, Mylan, Novartis, Roche, Sanofi Genzyme, Teva and TG Therapeutics.

SH has received unrestricted educational grants or speaking honoraria from Biogen, Merck Serono, Novartis, Roche, and Sanofi-Aventis.

OP has received honoraria and travel expenses from Biogen, Bayer, Genzyme, Merck, Novartis, Roche, and Teva. He has served on advisory boards for Biogen, Celgene, Novartis, Genzyme, Merck, and Roche.

DR has received consulting fees from Bayer, Celgene, Biogen, Janssen-Cilag, MedDay, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva Neuroscience. He has received research support from Actelion, Biogen, GW Pharma, Janssen-Cilag, MedDay, Merck Serono, Mitsubishi, Novartis, Sanofi Genzyme, Teva Neuroscience, and TG Therapeutics.

ET has received consulting or speaker honoraria from Roche, Novartis, and Takeda and travel expenses to attend educational meetings from Biogen, Merck, and Roche.

RdN is the Chair of the NIHR Research for Patient Benefit East Midlands Research Advisory Committee. He has received funding to prepare and deliver lectures on cognitive rehabilitation in multiple sclerosis from Novartis and Biogen.

RN has received support for advisory boards and travel from Novartis, Roche, and Biogen. He has received grant support from the UK MS Society. He is a member of a NICE HTA committee.

NE has served as a member of advisory boards for Biogen, Merck, Novartis, and Roche. He has received grant income from the UK MS Society, MRC, PCORI and NIHR.

## REFERENCES

1. Marrodan M, Alessandro L, Farez MF, et al. The role of infections in multiple sclerosis. *Multiple Sclerosis Journal* 2019;25(7):891-901.
2. Sharifian-Dorche M, Sahraian MA, Fadda G, et al. COVID-19 and Disease-Modifying Therapies in Patients with Demyelinating Diseases of the Central Nervous System: A Systematic Review. *Multiple Sclerosis and Related Disorders* 2021:102800.
3. Moss BP, Mahajan KR, Bermel RA, et al. Multiple sclerosis management during the COVID-19 pandemic. *Multiple Sclerosis Journal* 2020;26(10):1163-71.
4. Evangelou N, Garjani A, Hunter R, et al. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. *Journal of Neurology, Neurosurgery & Psychiatry* 2020
5. STROBE Statement. STROBE checklists 2007 [Version 4:[Available from: <https://www.strobe-statement.org/index.php?id=available-checklists> accessed February 2021.
6. Leddy S, Hadavi S, McCarren A, et al. Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. *Journal of neurology* 2013;260(10):2505-10.
7. Marrie RA, Zhang L, Lix LM, et al. The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. *Multiple sclerosis and related disorders* 2018;20:9-15.
8. Rohrer JM. Thinking clearly about correlations and causation: Graphical causal models for observational data. *Advances in Methods and Practices in Psychological Science* 2018;1(1):27-42.

9. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. *Epidemiology* 1999;37-48.
10. Sibley W, Bamford C, Clark K. Clinical viral infections and multiple sclerosis. *The Lancet* 1985;325(8441):1313-15.
11. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society* 1994;36(S1):S25-S28.
12. Edwards S, Zvartau M, Clarke H, et al. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. *Journal of Neurology, Neurosurgery & Psychiatry* 1998;64(6):736-41.
13. Buljevac D, Flach H, Hop W, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. *Brain* 2002;125(5):952-60.
14. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. *Neurology* 2006;67(4):652-59.
15. Schriefer D, Haase R, Ettle B, et al. Patient-versus physician-reported relapses in multiple sclerosis: insights from a large observational study. *European Journal of Neurology* 2020;27(12):2531-38.
16. De Angelis F, John NA, Brownlee WJ. Disease-modifying therapies for multiple sclerosis. *bmj* 2018;363
17. Merckelbach H, Dandachi-FitzGerald B, van Helvoort D, et al. When patients overreport symptoms: More than just malingering. *Current Directions in Psychological Science* 2019;28(3):321-26.